Alpha Synuclein Seeding Assays (Rt Quic Pmca) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Alpha-Synuclein Seeding Assay | |
|---|---|
| Full Name | Real-Time Quaking-Induced Conversion |
| Abbreviation | RT-QuIC |
| Alternative | Protein Misfolding Cyclic Amplification (PMCA) |
| Detection | α-Synuclein aggregation seeding activity |
| Sample Type | CSF, Skin, Olfactory mucosa |
| Sensitivity | >90% for PD, ~95% for DLB |
Alpha-Synuclein Seeding Assays represent a breakthrough in the detection of synucleinopathies. These ultra-sensitive tests detect the pathological seeding ability of misfolded α-synuclein protein, rather than just measuring protein concentration. The two primary methods are:
These assays can detect α-synuclein pathology in living patients with high sensitivity and specificity, enabling early and accurate diagnosis of Parkinson's disease, Dementia with Lewy Bodies, and Multiple System Atrophy.
Unlike conventional biomarker assays that measure total α-synuclein protein, seeding assays detect the infectious/aggregating capability of the protein:
Patient CSF → Add to reaction mix (recombinant α-syn + ThT)
↓
Repeated quaking (1 min) + incubation (30 min) cycles
↓
Seed-induced fibril formation
↓
Thioflavin T binding → Fluorescence detection
↓
Positive = Pathological seeding activity present
Patient CSF/ tissue → Incubation with α-syn monomer
↓
Sonication (breaks fibrils, creates new seeds)
↓
Repeated cycles (24-48 hours)
↓
Immunoblot detection of aggregated α-syn
| Parameter | Value |
|---|---|
| Sensitivity | 88-95% |
| Specificity | 90-100% |
| Sample | CSF |
Clinical utility:
| Parameter | Value |
|---|---|
| Sensitivity | 92-96% |
| Specificity | 87-100% |
| Sample | CSF |
DLB patients show high positive rates, helping distinguish from Alzheimer's disease.
| Parameter | Value |
|---|---|
| Sensitivity | 80-90% |
| Specificity | 85-95% |
| Sample | CSF |
MSA shows distinct seeding patterns compared to PD/DLB, enabling differential diagnosis.
| Disease | RT-QuIC Positivity |
|---|---|
| Parkinson's Disease | ~90-95% |
| Dementia with Lewy Bodies | ~92-96% |
| Multiple System Atrophy | ~80-90% |
| Progressive Supranuclear Palsy | ~10-20% |
| Corticobasal Degeneration | ~15-25% |
| Alzheimer's Disease | ~0-5% |
| Healthy Controls | ~0-5% |
The most validated sample type:
Emerging sample types with high promise:
| Metric | Value | 95% CI |
|---|---|---|
| Sensitivity (PD) | 91% | 85-95% |
| Specificity (PD vs HC) | 96% | 90-99% |
| Sensitivity (DLB) | 94% | 88-97% |
| Sensitivity (MSA) | 85% | 75-92% |
| Feature | Total α-Syn | Seeding Assay |
|---|---|---|
| What it measures | Protein concentration | Aggregation capability |
| Diagnostic specificity | Low | High |
| Early detection | Limited | Good |
| Disease progression | Weak correlation | Moderate correlation |
| Feature | p-α-Ser129 | Seeding Assay |
|---|---|---|
| What it measures | Modified protein | Pathological conformers |
| Sensitivity (PD) | ~85% | ~90-95% |
| Specificity | Moderate | High |
Seeding assays are increasingly used as:
Research is advancing toward blood-based seeding assays using:
Emerging research aims to distinguish:
Efforts underway for:
The study of Alpha Synuclein Seeding Assays (Rt Quic Pmca) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.